DLinDMA (Synonyms: 1,2-Dilinoleyloxy-N,N-dimethyl-3-aminopropane) |
Catalog No.GC33476
One-Click Copy Product Info
|
DLinDMA is a key lipid component of stable nucleic acid lipid particles as a benchmark.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 871258-12-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
DLinDMA is a key lipid component of stable nucleic acid lipid particles as a benchmark. DLinDMA can be used to deliver siRNA[1]. DLinDMA (1.56-25µM; 48h) showed no toxicity to HEK293 cells and SK-N-SH cells[2]. DLinDMA (25-200µM; 48h) dose-dependently inhibited the proliferation of HEK293 cells and SK-N-SH cells[2]. LNPs containing DLinDMA achieve more efficient gene silencing, as the lack of ester bonds renders them less susceptible to degradation by lipases[3]. As a key lipid component of nucleic acid lipid granules (SNALP), DLinDMA can deliver small interfering RNA (siRNA) in mice[1].
References:
[1] Semple SC, Akinc A,et,al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010 Feb;28(2):172-6. doi: 10.1038/nbt.1602. Epub 2010 Jan 17. PMID: 20081866.
[2] Vemana HP, Saraswat A, et,al. A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes. Nanomedicine (Lond). 2021 Jun;16(13):1081-1095.
[3] Lin PJ, Tam YY, et,al.Influence of cationic lipid composition on uptake and intracellular processing of lipid nanoparticle formulations of siRNA. Nanomedicine. 2013 Feb;9(2):233-46.
This plan is based on literature, please modify it to meet your specific needs.
Preparation of DLinDMA liposomes[1]
1) DLinDMA (5mM), DOPC (10mM), DOPE (2mM), and Cholesterol (2mM) were dissolved in ethanol.
2) The resulting organic phase was injected into the aqueous phase (Milli-Q water) to spontaneously form the liposomes.
3) Liposomal suspension was then probe sonicated at 30 amplitudes for 120s to obtain nanoliposomes.
4) The liposomes were stirred at room temperature to remove the traces of ethanol.
References:
[1] Vemana HP, Saraswat A, et,al. A novel gene therapy for neurodegenerative Lafora disease via EPM2A-loaded DLinDMA lipoplexes. Nanomedicine (Lond). 2021 Jun;16(13):1081-1095.
| Cas No. | 871258-12-7 | SDF | |
| Synonyms | 1,2-Dilinoleyloxy-N,N-dimethyl-3-aminopropane | ||
| Canonical SMILES | CCCCC/C=C\C/C=C\CCCCCCCCOCC(OCCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C | ||
| Formula | C41H77NO2 | M.Wt | 616.06 |
| Solubility | Ethanol : ≥ 100 mg/mL (162.32 mM);DMSO : < 1 mg/mL (insoluble or slightly soluble) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6232 mL | 8.1161 mL | 16.2322 mL |
| 5 mM | 324.6 μL | 1.6232 mL | 3.2464 mL |
| 10 mM | 162.3 μL | 811.6 μL | 1.6232 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 7 reference(s) in Google Scholar.)